7 results on '"Tancevski, Ivan"'
Search Results
2. Prevention of Oxidative Damage in Spinal Cord Ischemia Upon Aortic Surgery: First-In-Human Results of Shock Wave Therapy Prove Safety and Feasibility.
- Author
-
Graber, Michael, Nägele, Felix, Röhrs, Bernhard Tobias, Hirsch, Jakob, Pölzl, Leo, Moriggl, Bernhard, Mayr, Agnes, Troger, Felix, Kirchmair, Elke, Wagner, Julian Frederik, Nowosielski, Martha, Mayer, Lukas, Voelkl, Jakob, Tancevski, Ivan, Meyer, Dirk, Grimm, Michael, Knoflach, Michael, Holfeld, Johannes, and Gollmann-Tepeköylü, Can
- Published
- 2022
- Full Text
- View/download PDF
3. Vaccine based on folded receptor binding domain‐PreS fusion protein with potential to induce sterilizing immunity to SARS‐CoV‐2 variants.
- Author
-
Gattinger, Pia, Kratzer, Bernhard, Tulaeva, Inna, Niespodziana, Katarzyna, Ohradanova‐Repic, Anna, Gebetsberger, Laura, Borochova, Kristina, Garner‐Spitzer, Erika, Trapin, Doris, Hofer, Gerhard, Keller, Walter, Baumgartner, Isabella, Tancevski, Ivan, Khaitov, Musa, Karaulov, Alexander, Stockinger, Hannes, Wiedermann, Ursula, Pickl, Winfried F., and Valenta, Rudolf
- Subjects
CHIMERIC proteins ,SARS-CoV-2 ,BACTERIAL vaccines ,SARS-CoV-2 Omicron variant ,DNA vaccines ,COVID-19 pandemic - Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is responsible for the ongoing global COVID‐19 pandemic. One possibility to control the pandemic is to induce sterilizing immunity through the induction and maintenance of neutralizing antibodies preventing SARS‐CoV‐2 from entering human cells to replicate in. Methods: We report the construction and in vitro and in vivo characterization of a SARS‐CoV‐2 subunit vaccine (PreS‐RBD) based on a structurally folded recombinant fusion protein consisting of two SARS‐CoV‐2 Spike protein receptor‐binding domains (RBD) fused to the N‐ and C‐terminus of hepatitis B virus (HBV) surface antigen PreS to enable the two unrelated proteins serving as immunologic carriers for each other. Results: PreS‐RBD, but not RBD alone, induced a robust and uniform RBD‐specific IgG response in rabbits. Currently available genetic SARS‐CoV‐2 vaccines induce mainly transient IgG1 responses in vaccinated subjects whereas the PreS‐RBD vaccine induced RBD‐specific IgG antibodies consisting of an early IgG1 and sustained IgG4 antibody response in a SARS‐CoV‐2 naive subject. PreS‐RBD‐specific IgG antibodies were detected in serum and mucosal secretions, reacted with SARS‐CoV‐2 variants, including the omicron variant of concern and the HBV receptor‐binding sites on PreS of currently known HBV genotypes. PreS‐RBD‐specific antibodies of the immunized subject more potently inhibited the interaction of RBD with its human receptor ACE2 and their virus‐neutralizing titers (VNTs) were higher than median VNTs in a random sample of healthy subjects fully immunized with registered SARS‐CoV‐2 vaccines or in COVID‐19 convalescent subjects. Conclusion: The PreS‐RBD vaccine has the potential to serve as a combination vaccine for inducing sterilizing immunity against SARS‐CoV‐2 and HBV by stopping viral replication through the inhibition of cellular virus entry. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study.
- Author
-
Rass, Verena, Beer, Ronny, Schiefecker, Alois Josef, Kofler, Mario, Lindner, Anna, Mahlknecht, Philipp, Heim, Beatrice, Limmert, Victoria, Sahanic, Sabina, Pizzini, Alex, Sonnweber, Thomas, Tancevski, Ivan, Scherfler, Christoph, Zamarian, Laura, Bellmann‐Weiler, Rosa, Weiss, Günter, Djamshidian, Atbin, Kiechl, Stefan, Seppi, Klaus, and Loeffler‐Ragg, Judith
- Subjects
MENTAL illness ,COVID-19 ,MELAS syndrome ,QUALITY of life ,NEUROLOGICAL disorders ,NEUROLOGIC manifestations of general diseases ,PSYCHOLOGICAL manifestations of general diseases - Abstract
Background and purpose: To assess neurological manifestations and health‐related quality of life (QoL) 3 months after COVID‐19. Methods: In this prospective, multicenter, observational cohort study we systematically evaluated neurological signs and diseases by detailed neurological examination and a predefined test battery assessing smelling disorders (16‐item Sniffin Sticks test), cognitive deficits (Montreal Cognitive Assessment), QoL (36‐item Short Form), and mental health (Hospital Anxiety and Depression Scale, Posttraumatic Stress Disorder Checklist–5) 3 months after disease onset. Results: Of 135 consecutive COVID‐19 patients, 31 (23%) required intensive care unit (ICU) care (severe), 72 (53%) were admitted to the regular ward (moderate), and 32 (24%) underwent outpatient care (mild) during acute disease. At the 3‐month follow‐up, 20 patients (15%) presented with one or more neurological syndromes that were not evident before COVID‐19. These included polyneuro/myopathy (n = 17, 13%) with one patient presenting with Guillain‐Barré syndrome, mild encephalopathy (n = 2, 2%), parkinsonism (n = 1, 1%), orthostatic hypotension (n = 1, 1%), and ischemic stroke (n = 1, 1%). Objective testing revealed hyposmia/anosmia in 57/127 (45%) patients at the 3‐month follow‐up. Self‐reported hyposmia/anosmia was lower (17%) at 3 months, however, improved when compared to the acute disease phase (44%; p < 0.001). At follow‐up, cognitive deficits were apparent in 23%, and QoL was impaired in 31%. Assessment of mental health revealed symptoms of depression, anxiety, and posttraumatic stress disorders in 11%, 25%, and 11%, respectively. Conclusions: Despite recovery from the acute infection, neurological symptoms were prevalent at the 3‐month follow‐up. Above all, smelling disorders were persistent in a large proportion of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course.
- Author
-
Petzer, Verena, Schwendinger, Simon, Haschka, David, Vogi, Verena, Tymoszuk, Piotr, Burkert, Francesco, Sahanic, Sabina, Sonnweber, Thomas, Bellmann‐Weiler, Rosa, Loeffler‐Ragg, Judith, Tancevski, Ivan, Zschocke, Johannes, Weiss, Guenter, Wolf, Dominik, and Jukic, Emina
- Published
- 2021
- Full Text
- View/download PDF
6. LAMTOR/Ragulator regulates lipid metabolism in macrophages and foam cell differentiation.
- Author
-
Lamberti, Giorgia, De Smet, Cedric H., Angelova, Mihaela, Kremser, Leopold, Taub, Nicole, Herrmann, Caroline, Hess, Michael W., Rainer, Johannes, Tancevski, Ivan, Schweigreiter, Rüdiger, Kofler, Reinhard, Schmiedinger, Thomas, Vietor, Ilja, Trajanoski, Zlatko, Ejsing, Christer S., Lindner, Herbert H., Huber, Lukas A., and Stasyk, Taras
- Subjects
LIPID metabolism ,CELL differentiation ,LYSOSOMES ,FOAM cells ,BONE marrow ,SCAFFOLD proteins - Abstract
Late endosomal/lysosomal adaptor and MAPK and mTOR activator (LAMTOR/Ragulator) is a scaffold protein complex that anchors and regulates multiprotein signaling units on late endosomes/lysosomes. To identify LAMTOR‐modulated endolysosomal proteins, primary macrophages were derived from bone marrow of conditional knockout mice carrying a specific deletion of LAMTOR2 in the monocyte/macrophage cell lineage. Affymetrix‐based transcriptomic analysis and quantitative iTRAQ‐based organelle proteomic analysis of endosomes derived from macrophages were performed. Further analyses showed that LAMTOR could be a novel regulator of foam cell differentiation. The lipid droplet formation phenotype observed in macrophages was additionally confirmed in MEFs, where lipidomic analysis identified cholesterol esters as specifically downregulated in LAMTOR2 knockout cells. The data obtained indicate a function of LAMTOR2 in lipid metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
- Author
-
Gattinger P, Niespodziana K, Stiasny K, Sahanic S, Tulaeva I, Borochova K, Dorofeeva Y, Schlederer T, Sonnweber T, Hofer G, Kiss R, Kratzer B, Trapin D, Tauber PA, Rottal A, Körmöczi U, Feichter M, Weber M, Focke-Tejkl M, Löffler-Ragg J, Mühl B, Kropfmüller A, Keller W, Stolz F, Henning R, Tancevski I, Puchhammer-Stöckl E, Pickl WF, and Valenta R
- Subjects
- Antibodies, Viral, Epitopes, Humans, Spike Glycoprotein, Coronavirus genetics, COVID-19, SARS-CoV-2
- Abstract
Background: The determinants of successful humoral immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of critical importance for the design of effective vaccines and the evaluation of the degree of protective immunity conferred by exposure to the virus. As novel variants emerge, understanding their likelihood of suppression by population antibody repertoires has become increasingly important., Methods: In this study, we analyzed the SARS-CoV-2 polyclonal antibody response in a large population of clinically well-characterized patients after mild and severe COVID-19 using a panel of microarrayed structurally folded and unfolded SARS-CoV-2 proteins, as well as sequential peptides, spanning the surface spike protein (S) and the receptor-binding domain (RBD) of the virus., Results: S- and RBD-specific antibody responses were dominated by immunoglobulin G (IgG), mainly IgG
1 , and directed against structurally folded S and RBD and three distinct peptide epitopes in S2. The virus neutralization activity of patients´ sera was highly correlated with IgG antibodies specific for conformational but not sequential RBD epitopes and their ability to prevent RBD binding to its human receptor angiotensin-converting enzyme 2 (ACE2). Twenty percent of patients selectively lacked RBD-specific IgG. Only immunization with folded, but not with unfolded RBD, induced antibodies against conformational epitopes with high virus-neutralizing activity. Conformational RBD epitopes required for protection do not seem to be altered in the currently emerging virus variants., Conclusion: These results are fundamental for estimating the protective activity of antibody responses after natural infection or vaccination and for the design of vaccines, which can induce high levels of SARS-CoV-2-neutralizing antibodies conferring sterilizing immunity., (© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.